The use of Carnicetine in patients with diabetic polyneuropathy

Cover Page

Cite item

Full Text

Abstract

Polyneuropathy is a frequent complication of diabetes mellitus, associated with severe disability, a decrease in the quality of life of patients, an increased risk of death. Treatment of patients with diabetic polyneuropathy (DPNP) includes correction of carbohydrate metabolism, restoration of the structure and functions of nerve fibers, elimination of the most significant symptoms of the disease. At present, information on the efficacy of acetyl-L-carnitine (Carnitine) in such patients is accumulated. Information on its role in metabolism in normal and pathological conditions is considered. The results of randomized clinical trials and meta-analyzes on this issue are presented, which testify to the effectiveness of the drug in patients with DPNP.

About the authors

P. R Kamchatnov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: pavkam7@gmail.com
д-р мед. наук, проф. каф. неврологии и нейрохирургии с курсом фак-та усовершенствования врачей лечебного фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

A. A Kabanov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. неврологии и нейрохирургии с курсом фак-та усовершенствования врачей лечебного фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

S. B Khanmurzaeva

Dagestan State Medical University

аспирант каф. неврологии, нейрохирургии и медицинской генетики лечебного фак-та ФГБОУ ВО ДГМУ 367000, Russian Federation, Makhachkala, pl. Lenina, d. 1

A. V Chugunov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. неврологии, нейрохирургии и медицинской генетики лечебного фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

N. B Khanmurzaeva

Dagestan State Medical University

канд. мед. наук, ассистент каф. клин. фармакологии ФГБОУ ВО ДГМУ 367000, Russian Federation, Makhachkala, pl. Lenina, d. 1

References

  1. Visser N, Notermans N, Linssen R et al. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015; 84 (3): 259-64.
  2. Vincent A, Calabek B, Roberts L, Feldman E. Biology of diabetic neuropathy. Handb Clin Neurol 2013; 115: 591-606.
  3. Sachan D.S, Yatim A.M. Suppression of aflatoxin B1-induced lipid abnormalities and macromolecule - adduct formation by L-carnitine. J Environ Pathol Toxicol Oncol 1992; 11: 205-10.
  4. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004; 1033: 99-107.
  5. Rahbar A.R, Shakerhosseini R, Saadat N et al. Effect of L-carnitine on plasma glycemic andlipidemic profile in patients with type II diabetes mellitus. Eur J Clin Nutr 2005; 59: 592-6.
  6. Power R.A, Hulver M.W, Zhang J.Y et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007; 50: 824-832. doi: 10.1007/s00125-007-0605-4
  7. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990; 81: 402-6.
  8. Levine J, Panchalingam K, Mc Clure R.J et al. Effects of acetyl - L - carnitine and myo - inositol on high - energy phosphate and membrane phospholipid metabolism in zebra fish: a 31P - NMR - spectroscopy study. Neurochem Res 2003; 28: 687-90.
  9. Vivoli E, Di Cesare Mannelli L et al. Acetyl - l - carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience. 2010; 167: 1168-74. http://dx.doi.org/10.1016/j.neuroscience.2010.03.017.
  10. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J CellSci 2003; 116 (Pt 19): 3855-62.
  11. Baloh R.H, Tansey M.G, Lampe P.A et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998; 21 (6): 1291-302.
  12. Traina G. The neurobiology of acetyl - L - carnitine. Front Biosci (Landmark Ed) 2016; 21: 1314-29.
  13. Ido Y, Mc Howat J, Chang K.C et al. Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl - L - carnitine. Diabetes 1994; 43: 1469-77. http://dx.doi.org/10.2337/di-abetes. 43.12.1469
  14. Chiechio S, Copani A, Iv R.W.G, Nicoletti F. Acetyl - L - carnitine in neuropathic pain. CNS Drugs 2007; 21 (1): 31-8.
  15. Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 2012; 28: 166-76. http://dx.doi.org/10.1097/MOG.0b013e3283505a3b
  16. Watson J.C, Dyck P.J.B. Peripheral neuropathy: a practical approach to diagnosis and symptom management. Mayo Clin Proc 2015; 90: 940-51. http:// dx.doi.org/10.1016/j.mayocp.2015.05.004.
  17. Acetyl - L - carnitine. Monograph. Altern Med Rev 2010; 15: 76-83.
  18. Curti D, Dagani F, Galmozzi M.R, Marzatico F. Effect of aging and acetyl - L - carnitine on energetic and cholinergic metabolism in rat brain regions. Mech Ageing Dev 1989; 47: 39-45. PMID: 2542702
  19. Onofrj M, Ciccocioppo F, Varanese S et al. Acetyl - L - carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother 2013; 13: 925-36. doi: 10.1586/14737175.2013.814930 PMID: 23965166
  20. Scarpini E, Doneda P, Pizzul S et al. L-carnitine and acetyl - L - carnitine in human nerves from normal and diabetic subjects. J Peripher Nerv Syst 1996; 1: 157-63.
  21. Li S, Li Q, Li Y et al. Acetyl - L - carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta - analysis of randomized controlled trials. Plos One 2015; 10: 1-10. http://dx.doi.org/10.1371/ journal.pone.0119479.
  22. Pessoa B, Escudeiro G, Nascimento O. Emerging Treatments for Neuropathic Pain. Curr Pain Headache Rep 2015; 19: 56-60.
  23. De Grandis D, Minardi C. Acetyl - L - carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long - term, randomised, double - blind, placebo - controlled study. Drugs R&D 2002; 3: 223-31.
  24. Sima A.A, Calvani M, Mehra M, Amato A. Acetyl - l - carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy an analysis of two randomized placebo - controlled trials. Diabetes Care 2005; 28: 89-94.
  25. Li S, Chen X, Li Q et al. Effects of acetyl - L - carnitine andmethylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double - blind, controlled trial. J Diabetes Invest 2016; 7: 777-785. doi: 10.1111/jdi.12493
  26. Veronese N, Sergi G, Stubbs B, the EUGMS special interest group on diabetes. Effect of acetyl - l - carnitine in the treatment of diabetic peripheral neuropathy: A systematic review and meta - analysis. Eur Geriatr Med 2017. http://dx.doi.org/10.1016/j.eurger.2017.01.002
  27. Mondal S, Choudhury K.B, Sharma S et al. Comparative study among glutamine, acetyl - L - carnitine, vitamin - E and methylcobalamine for treatment of paclitaxel - induced peripheral neuropathy. Clin Cancer Investig J 2014; 3: 213-9.
  28. Youle M, Osio M. A double - blind, parallel - group, placebo - controlled, multicentre study of acetyl L - carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8: 241-50.
  29. Herzmann C, Johnson M.A, Youle M. Long - term effect of acetyl - L - carnitine for antiretroviral toxic neuropathy. HIV ClinTrials 2005; 6: 344-50.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies